Abstract:Interleukin (IL)-6 is a pleiotropic cytokine that not only affects the immune system, but also acts in other biological systems and many physiological events in various organs. In a target cell, IL-6 can simultaneously generate functionally distinct or sometimes contradictory signals through its receptor complex, IL-6Rα and gp130. One good illustration is derived from the in vitro observations that IL-6 promotes the growth arrest and differentiation of M1 cells through gp130-mediated STAT3 activation, whereas the Y759/SHP-2-mediated cascade by gp130 stimulation has growth-enhancing effects. The final physiological output can be thought of as a consequence of the orchestration of the diverse signaling pathways generated by a given ligand. This concept, the signal orchestration model, may explain how IL-6 can elicit proinflammatory or anti-inflammatory effects, depending on the in vivo environmental circumstances. Elucidation of the molecular mechanisms underlying this issue is a challenging subject for future research. Intriguingly, recent in vivo studies indicated that the SHP-2-binding site- and YXXQ-mediated pathways through gp130 are not mutually exclusive but affect each other: a mutation at the SHP-2-binding site prolongs STAT3 activation, and a loss of STAT activation by gp130 truncation leads to sustained SHP-2/ERK MAPK phosphorylation. Although IL-6/gp130 signaling is a promising target for drug discovery for many human diseases, the interdependence of each signaling pathway may be an obstacle to the development of a nonpeptide orally active small molecule to inhibit one of these IL-6 signaling cascades, because it would disturb the signal orchestration. In mice, a consequence of the imbalanced signals causes unexpected results such as gastrointestinal disorders, autoimmune diseases, and/or chronic inflammatory proliferative diseases. However, lessons learned from IL-6 KO mice indicate that IL-6 is not essential for vital biological processes, but a significant impact on disease progression in many experimental models for human disorders. Thus, IL-6/gp130 signaling will become a more attractive therapeutic target for human inflammatory diseases when a better understanding of IL-6 signaling, including the identification of the conductor for gp130 signal transduction, is achieved.

Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

More and more pleiotropy within the IL‐6 family of cytokines

IL-6 signal transduction and its physiological roles: the signal orchestration model

Structure‐function analysis of human IL‐6 receptor: dissociation of amino acid residues required for IL‐6‐binding and for IL‐6 signal transduction through gp130.

Synthetic trimeric interleukin-6 receptor complexes with a STAT3 phosphorylation dominated activation profile

Targeting IL-6 trans-signalling: past, present and future prospects

Function and molecular modeling of the interaction between human interleukin 6 and its HNK-1 oligosaccharide ligands

Structural insights into IL-11-mediated signalling and human IL6ST variant-associated immunodeficiency

Nonspecific Inhibition of IL6 Family Cytokine Signalling by Soluble gp130

Notch ligand Delta-1 differentially modulates the effects of gp130 activation on interleukin-6 receptor alpha-positive and -negative human hematopoietic progenitors

Effects of soluble gp130 and its antisense RNA on activities of target genes induced by IL-6

Progress in the Research of Structure and Function of Interleukin-6 Receptor

Structural biology of shared cytokine receptors.

Interleukin‐11 receptor is an alternative α‐receptor for interleukin‐6 and the chimeric cytokine IC7

Unveiling novel insights into human IL-6 - IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis

Advances in Structural Base of Interaction Between Hil-6 and Its Receptor and Antagonist of Hil-6

Two Signals Are Necessary for Cell Proliferation Induced by a Cytokine Receptor gp130: Involvement of STAT3 in Anti-Apoptosis

Unpaired cysteine insertions favor transmembrane dimerization and induce ligand-independent constitutive cytokine receptor signaling

Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression

Ironing Out the Mechanism of gp130 Signaling